Closing the TB detection gap: notify, test, and trace the missing cases before MDR-TB compounds

Diagnosis

Tuberculosis remains a tier-1 communicable disease burden in Bangladesh. The curated characterization puts it at roughly 280,000 incident cases per year, with a multidrug-resistant TB (MDR-TB) sub-burden layered on top. Two features make this urgent now. First, an incident caseload at this scale means transmission is sustained year on year: every case that goes undetected or partially treated seeds new infections, so the burden is self-renewing rather than self-limiting. Second, the MDR-TB sub-burden is the part of the problem that gets worse the longer the system underperforms. Resistance is manufactured by interrupted, incomplete, or unsupervised treatment, so a detection-and-adherence gap today becomes a far more expensive, harder-to-cure resistant caseload tomorrow. The lead responsible body is the Directorate General of Health Services (DGHS), with the Department of Public Health Engineering (DPHE) as a supporting body. The policy task is not to discover the disease, which is well characterized, but to convert a known caseload into reliably detected, fully treated, and traced cases before the resistant fraction compounds.

Recommended actions

1. Mandatory case notification, public and private. Owner: DGHS, through the National Tuberculosis Control Programme. Mechanism: a DGHS circular making TB a mandatory-notifiable condition for every diagnosing facility, including private clinics, diagnostic labs, and pharmacies dispensing anti-TB drugs, reporting into a single national TB register. Observable signal: the share of the estimated 280,000 incident cases that appear in the register rises quarter over quarter, narrowing the gap between estimated and notified cases.
2. Decentralize rapid molecular diagnosis and resistance testing. Owner: DGHS. Mechanism: a procurement and placement plan that puts rapid molecular testing (which detects both TB and drug resistance in one run) at upazila level, financed through a dedicated DGHS budget line, so that every notified case is tested for resistance at diagnosis rather than after treatment failure. Observable signal: the proportion of notified cases with a documented drug-susceptibility result at diagnosis climbs, and MDR-TB cases are caught earlier in their course.
3. Treat adherence as the core control measure. Owner: DGHS, National Tuberculosis Control Programme. Mechanism: a standardized adherence-support protocol (community treatment supporters, digital adherence reminders, and a uniform drug-stock policy that prevents stock-outs at the facility that holds the patient's register). Observable signal: treatment-completion rates rise and the number of cases lost to follow-up falls, which is the single most direct brake on new MDR-TB generation.
4. Contact tracing and preventive treatment around every confirmed case. Owner: DGHS, with DPHE supporting on the environmental and water-sanitation conditions that concentrate transmission risk. Mechanism: a contact-investigation protocol triggered automatically by each register notification, screening household and close contacts and offering preventive treatment where indicated. Observable signal: contacts screened per notified case rises from near zero toward full coverage.
5. Make the MDR-TB pathway a named, funded sub-programme. Owner: DGHS. Mechanism: a ring-fenced MDR-TB treatment line with guaranteed second-line drug supply and dedicated treatment sites, so resistant cases are not managed on the standard pathway by default. Observable signal: confirmed MDR-TB cases enrolled on an appropriate regimen within a fixed window of diagnosis.

Sequencing (first 12 months)

Start with the notification circular, because nothing else can be measured or targeted until the true detected caseload is visible and private-sector cases stop disappearing. The register is the spine that the other four actions hang on. In parallel, begin the molecular-testing placement plan, since resistance testing at diagnosis is what turns notification into early MDR-TB capture. Once notification volume and resistance results are flowing, layer the adherence protocol and contact tracing on top, because both are driven off register entries. The MDR-TB sub-programme is stood up last in the year but designed first, so that the resistant cases the new testing reveals have somewhere to go.

Risks and constraints

The binding constraints are fiscal and administrative, not technical. Mandatory private-sector notification depends on enforcement capacity DGHS may not yet have, and a circular without follow-through becomes a stale label. Decentralized molecular testing and a ring-fenced MDR-TB line both compete for scarce health budget, so without a protected budget line they will be deferred. Drug-supply continuity is the quiet make-or-break: stock-outs convert a treatment programme into a resistance-generating machine, the opposite of its purpose.

Bottom line

Bangladesh's roughly 280,000 annual TB cases are a known, self-renewing burden whose resistant fraction grows precisely where detection and adherence fail, so the policy job is execution, not discovery. DGHS should lead with mandatory notification and resistance testing at diagnosis, then adherence and contact tracing, with a funded MDR-TB pathway to absorb what the new testing reveals.